Neuroblastoma: Difference between revisions
Jump to navigation
Jump to search
Jensflorian (talk | contribs) →Classification/grading: INRGSS |
|||
| (One intermediate revision by the same user not shown) | |||
| Line 9: | Line 9: | ||
Laboratory findings: | Laboratory findings: | ||
*Increased urine homovanillic acid. | *Increased urine homovanillic acid. | ||
Imaging: | |||
*mIBG uptake (>90% neuroblastomas) | |||
Predictors of a poor prognosis:<ref name=Ref_PCPBoD8_254>{{Ref PCPBoD8|254}}</ref> | Predictors of a poor prognosis:<ref name=Ref_PCPBoD8_254>{{Ref PCPBoD8|254}}</ref> | ||
| Line 16: | Line 20: | ||
*Near ploidy. | *Near ploidy. | ||
*N-MYC amplification. | *N-MYC amplification. | ||
*1p deletion /imbalance | |||
*Lymph node spread. | *Lymph node spread. | ||
*Distant spread. | *Distant spread. | ||
| Line 91: | Line 96: | ||
*Mitoses/karyorrhectic cells. | *Mitoses/karyorrhectic cells. | ||
*Molecular abnormalities. | *Molecular abnormalities. | ||
International Neuroblastoma Risk Group Staging System (INRGSS) | |||
* L1: Locoregional tumor without Image-Definging Risk factors (IDRFs) | |||
* L2: Locoregional tumor with one or more IDRFs | |||
* M: Distant metastatic disease (except Ms) | |||
* Ms: INRG Stage L1 or L2 tumor with metastatic disease confined to skin and/or liver and/or bone marrow and age below 18 months. | |||
==IHC== | ==IHC== | ||